TY - JOUR T1 - An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00447-2021 SP - 00447-2021 AU - Rayid Abdulqawi AU - Imran Satia AU - Kimberley J Holt AU - Rachel Dockry AU - Shilpi Sen AU - Jaclyn A Smith Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/07/15/23120541.00447-2021.abstract N2 - Refractory chronic cough (RCC) is defined as cough lasting longer than eight weeks either in the absence of an identifiable underlying cause or that remains resistant to treating any potential underlying causes [1]. Affected patients have a poor quality of life and suffer from fatigue, disturbed sleep, incontinence, frustration, anxiety, and depression [2]. Despite being a debilitating condition, there is no licensed treatment available.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Abdulqawi reports personal fees from AstraZeneca, personal fees from Boehringer-Ingleheim, personal fees from Mundipharma, outside the submitted work; .Conflict of interest: Dr. Satia reports personal fees from Astrazeneca, grants and personal fees from Merck Canada, grants from ERS Respire 3 Marie Curie Fellowship, grants from E..J. Moran Campbell Early Career Award, grants and personal fees from GSK, outside the submitted work; .Dr. Satia reports personal fees from Educational Talks for GPs; GSK, Astrazeneca, grants and personal fees from Merck Canada, grants from ERS Respire 3 Marie Curie Fellowship, outside the submitted work; .Conflict of interest: Dr. Holt has nothing to disclose.Conflict of interest: Dr. Dockry has nothing to disclose.Conflict of interest: Dr. Sen has nothing to disclose.Conflict of interest: Dr. Smith reports grants and personal fees from Glaxosmithkline, NeRRe Pharmaceuticals, Menlo, Bayer, Boehringer Ingleheim, Axalbion, Afferent, Merck personal fees from Genentech, Neomed, Bellus, Chiesi, AstraZeneca, Algernon, non-financial support from Vitalograph, outside the submitted work; In addition, Dr. Smith has a patent A method for generating output data licensed. ER -